Published On: Wed, Oct 19th, 2016

Upgrades And Downgrades For Eli Lilly And Company (NYSE:LLY)


Recently stock market analysts have updated their consensus ratings on shares of Eli Lilly and Company (NYSE:LLY).

Most recent broker ratings

10/03/2016 – Eli Lilly and Company had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 94 price target on the stock.

09/27/2016 – Eli Lilly and Company was upgraded to “buy” by analysts at Goldman Sachs. They now have a USD 95 price target on the stock.

09/08/2016 – Eli Lilly and Company was upgraded to “overweight” by analysts at JP Morgan. They now have a USD 95 price target on the stock.

08/10/2016 – Eli Lilly and Company had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 105 price target on the stock.

08/02/2016 – Eli Lilly and Company had its “buy” rating reiterated by analysts at Citigroup.

07/14/2016 – Eli Lilly and Company had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 105 price target on the stock.

06/03/2016 – Eli Lilly and Company had its “equal weight” rating reiterated by analysts at Morgan Stanley. They now have a USD 88 price target on the stock.

04/25/2016 – Eli Lilly and Company had its “overweight” rating reiterated by analysts at Credit Suisse.

04/06/2016 – Societe Generale began new coverage on Eli Lilly and Company giving the company a “hold” rating. They now have a USD 78 price target on the stock.

02/10/2016 – Eli Lilly and Company had its “buy” rating reiterated by analysts at Deutsche Bank.

02/04/2016 – Eli Lilly and Company had its “buy” rating reiterated by analysts at Berenberg Bank. They now have a USD 106 price target on the stock.

01/29/2016 – Eli Lilly and Company had its “outperform” rating reiterated by analysts at Sanford C. Bernstein. They now have a USD 92 price target on the stock.

01/15/2016 – Eli Lilly and Company had its “buy” rating reiterated by analysts at Argus. They now have a USD 93 price target on the stock.

12/21/2015 – Eli Lilly and Company had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 108 price target on the stock.

12/18/2015 – Atlantic Equities began new coverage on Eli Lilly and Company giving the company a “overweight” rating. They now have a USD 100 price target on the stock.

Eli Lilly and Company has a 50 day moving average of 79.75 and a 200 day moving average of 77.96. The stock’s market capitalization is 83.31B, it has a 52-week low of 67.88 and a 52-week high of 88.16.

The share price of the company (NYSE:LLY) was up +0.31% during the last trading session, with a high of 79.14 and the volume of Eli Lilly and Company shares traded was 3218290.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.